Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan

Osteoporosis International

Volumn 24, Issue 2, 2013, Pages 511-521

  Soong, Y K ^a   Tsai, K S ^b   Huang, H Y ^a   Yang, R S ^b   Chen, J F ^c   Wu, P C H ^d   Huang, K E ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bisphosphonate therapy; Compliance; Medication possession ratio; Osteoporosis; Refracture

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEATH; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TAIWAN;

EID: 84873742404     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-1984-z     Document Type: Article

References (33)

1. Chie WC, Yang RS, Liu JP, Tsai KS (2004) High incidence rate of hip fracture in Taiwan: estimated from a Nationwide Health Insurance database. Osteoporos Int 15:998-1002
2. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026
3. Tsai KS, Tai TY (1997) Epidemiology of osteoporosis in Taiwan. Osteoporos Int 7(Suppl 3):S96-S98
4. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521
5. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285:785-795
6. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S-17S, discussion 17S-19S
7. Sweet MG, Sweet JM, Jeremiah MP, Galazka SS (2009) Diagnosis and treatment of osteoporosis. Am Fam Physician 79:193-200
8. Association T.T.O. (2007) Osteoporosis treatment guideline. http://www.toa1997.org.tw. Accessed May 12 2009
9. Yang NP, Deng CY, Chou YJ, Chen PQ, Lin CH, Chou P, Chang HJ (2006) Estimated prevalence of osteoporosis from a Nationwide Health Insurance database in Taiwan. Health Policy 75:329-337
10. Chow SN, Huang CC, Lee YT (1997) Demographic characteristics and medical aspects of menopausal women in Taiwan. J Formos Med Assoc 96:806-811
11. Graham R, Russell G (2011) Bisphosphonates: The first 40 years. Bone 49:2-19
12. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569-1575
13. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414-2419
14. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
15. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856-861
16. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
17. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652
18. Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585-594
19. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511-517
20. Shao CJ, Hsieh YH, Tsai CH, Lai KA (2009) A nationwide seven-year trend of hip fractures in the elderly population of Taiwan. Bone 44:125-129
21. Chevalley T, Guilley E, Herrmann FR, Hoffmeyer P, Rapin CH, Rizzoli R (2007) Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 40:1284-1289
22. Finsen V, Johnsen LG, Trano G, Hansen B, Sneve KS (2004) Hip fracture incidence in central Norway: a followup study. Clin Orthop Relat Res 173-178
23. Hagino H, Katagiri H, Okano T, Yamamoto K, Teshima R (2005) Increasing incidence of hip fracture in Tottori Prefecture, Japan: trend from 1986 to 2001. Osteoporos Int 16:1963-1968
24. Wang Y, Tao Y, Hyman ME, Li J, Chen Y (2009) Osteoporosis in China. Osteoporos Int 20:1651-1662
25. Lau EM, Cooper C, Fung H, Lam D, Tsang KK (1999) Hip fracture in Hong Kong over the last decade-a comparison with the UK. J Public Health Med 21:249-250
26. Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449-457
27. Sheehy O, Kindundu C, Barbeau M, LeLorier J (2009) Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int 20:1583-1594
28. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97
29. Chen HF, Ho CA, Li CY (2008) Increased risks of hip fracture in diabetic patients of Taiwan: a population-based study. Diabetes Care 31:75-80
30. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453-1460
31. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337-344
32. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638-1644
33. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914-921